title: NAD(P)H oxidase inhibitor prevents blood pressure elevation and cardiovascular hypertrophy in aldosterone-infused rats.
abstract: Increased bioavailability of reactive oxygen species (ROS) has been implicated in the pathogenesis of mineralocorticoid hypertension. To find out the source of ROS, we evaluated the role of NAD(P)H oxidase in blood pressure (BP) elevation, cardiovascular hypertrophy, and fibrosis in aldosterone-salt rats. Aldosterone infusion (0.75 microg/h) significantly increased BP, which is attenuated by apocynin (1.5 mmol/L). Cardiac hypertrophy developed by aldosterone infusion was also normalized with apocynin. Greater mRNA for p22phox and NAD(P)H oxidase activity (more than twofold) in aorta of aldosterone-infused rats was reduced in apocynin-treated rats. Aldosterone infusion increased marginally procollagen I and III expression in LV compared to controls and apocynin decreased procollagen. Masson's Trichrome stain showed increased cardiac perivascular fibrosis, which was reduced by apocynin. These results suggest that NAD(P)H oxidase plays an important role in cardiovascular damage associated with mineralocorticoid hypertension.
authors.affiliation: Department of Medicine/Cardiology, Samsung Cheil Hospital, Sungkyunkwan University School of Medicine and Samsung Biomedical Research Institute, Seoul, Republic of Korea.
authors.forename: Young Mee
authors.initials: YM
authors.lastname: Park
authors.forename: Mi Young
authors.initials: MY
authors.lastname: Park
authors.forename: Yeon-Lim
authors.initials: YL
authors.lastname: Suh
authors.forename: Jeong Bae
authors.initials: JB
authors.lastname: Park
mesh_terms: D000098:Acetophenones / Q000494:pharmacology; D000450:Aldosterone / Q000494:pharmacology*; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology; D001011:Aorta / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects*; D003094:Collagen / Q000378:metabolism; D005355:Fibrosis; D006352:Heart Ventricles / Q000378:metabolism; D006973:Hypertension / Q000517:prevention & control*; D006984:Hypertrophy / Q000517:prevention & control*; D008297:Male; D026901:Membrane Transport Proteins; D009247:NADH, NADPH Oxidoreductases / Q000037:antagonists & inhibitors*; D009252:NADPH Dehydrogenase / Q000378:metabolism; D019255:NADPH Oxidases; D018384:Oxidative Stress; D010750:Phosphoproteins / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D017382:Reactive Oxygen Species; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013997:Time Factors
chemical_list: D000098:Acetophenones; D000959:Antihypertensive Agents; D026901:Membrane Transport Proteins; D010750:Phosphoproteins; D012333:RNA, Messenger; D017382:Reactive Oxygen Species; D000450:Aldosterone; D003094:Collagen; C056165:acetovanillone; D009247:NADH, NADPH Oxidoreductases; D019255:NADPH Oxidases; C086986:CYBA protein, human; D009252:NADPH Dehydrogenase